Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma

Zhang, Yanyu; Zhang, Li; Hu, Yang; Jiang, Kuan; Li, Zhuoquan; Lin, Yao‐Zhong; Wei, Gang; Lu, Weiyue

doi:10.1016/j.jconrel.2018.09.016

Cited by 39 publications

(18 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Wei‐Lin's group, CB5005‐modified liposomes penetrated the BBB, targeted gliomas, and delivered doxorubicin into the nucleus of cells. in vivo imaging revealed that the formulation accumulated at the tumor xenograft and intracranial GBM in different animal models and lengthened the survival time of mice (Y. Zhang et al, ).…”

Section: Lipid‐based Nanosystemsmentioning

confidence: 99%

Immunoengineering in glioblastoma imaging and therapy

Zanganeh

Georgala

Corbo

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Patients diagnosed with glioblastoma have poor prognosis. Conventional treatment strategies such as surgery, chemotherapy, and radiation therapy demonstrated limited clinical success and have considerable side effects on healthy tissues. A central challenge in treating brain tumors is the poor permeability of the blood–brain barrier (BBB) to therapeutics. Recently, various methods based on immunotherapy and nanotechnology have demonstrated potential in addressing these obstacles by enabling precise targeting of brain tumors to minimize adverse effects, while increasing targeted drug delivery across the BBB. In addition to treating the tumors, these approaches may be used in conjunction with imaging modalities, such as magnetic resonance imaging and positron emission tomography to enhance the prognosis procedures. This review aims to provide mechanistic understanding of immune system regulation in the central nervous system and the benefits of nanoparticles in the prognosis of brain tumors. This article is characterized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Cells at the Nanoscale Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

Section: Lipid‐based Nanosystemsmentioning

confidence: 99%

Immunoengineering in glioblastoma imaging and therapy

Zanganeh

Georgala

Corbo

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Cell delivery of therapeutic peptides in the cancer sphere has been undertaken by a variety of different routes involving liposomes [47], nanoparticles [48] and short cell-penetrating sequences (reviewed [49]). Our peptide is conjugated to Cell Porter® (Portage Pharmaceuticals Limited), a patented cell penetrating peptide based on the human HOXD12 protein [25–27].…”

Section: Discussionmentioning

confidence: 99%

Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

Blair

Walsh

Littman³

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

BackgroundRecent advances in the treatment of melanoma that involve immunotherapy and B-Raf inhibition have revolutionised cancer care for this disease. However, an un-met clinical need remains in B-Raf inhibitor resistant patients where first-generation B-Raf inhibitors provide only short-term disease control. In these cases, B-Raf inhibition leads to paradoxical activation of the C-Raf – MEK – ERK signalling pathway, followed by metastasis. PDE8A has been shown to directly interact with and modulate the cAMP microdomain in the vicinity of C-Raf. This interaction promotes C-Raf activation by attenuating the PKA-mediated inhibitory phosphorylation of the kinase.MethodsWe have used a novel cell-penetrating peptide agent (PPL-008) that inhibits the PDE8A – C-Raf complex in a human malignant MM415 melanoma cell line and MM415 melanoma xenograft mouse model to investigate ERK MAP kinase signalling.ResultsWe have demonstrated that the PDE8A – C-Raf complex disruptor PPL-008 increased inhibitory C-Raf-S259 phosphorylation and significantly reduced phospho-ERK signalling. We have also discovered that the ability of PPL-008 to dampen ERK signalling can be used to counter B-Raf inhibitor-driven paradoxical activation of phospho-ERK in MM415 cells treated with PLX4032 (Vemurafenib). PPL-008 treatment also significantly retarded the growth of these cells. When applied to a MM415 melanoma xenograft mouse model, PPL-008C penetrated tumour tissue and significantly reduced phospho-ERK signalling in that domain.ConclusionOur data suggests that the PDE8A-C-Raf complex is a promising therapeutic treatment for B-Raf inhibitor resistant melanoma.Electronic supplementary materialThe online version of this article (10.1186/s12885-019-5489-4) contains supplementary material, which is available to authorized users.

show abstract

“…Over the last few decades, advancements in the field of nanotechnology and material sciences have led to a major breakthrough in the fabrication of various NMs composed of DNA ( Dai et al, 2017 ; Jiang et al, 2017 ), polymers ( Chang et al, 2018 ; Simpson et al, 2019 ), carbon ( Teradal and Jelinek, 2017 ; Jiang et al, 2019 ), metals ( Dhivya et al, 2015 ; Singh, 2018 ), composites ( Song et al, 2015 ; Zhai et al, 2018 ), liposomes ( Zhang et al, 2011 ; Lorente et al, 2018 ; Zhang et al, 2018 ), et cetera for cancer therapy. Synthesis of NMs allows the materials to be fine-tuned to tailor their properties (e.g., size, composition, surface properties, etc.)…”

Section: Mechanism Of Immunomodulation By Nanomaterialsmentioning

confidence: 99%

Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics

2021

View full text Add to dashboard Cite

Immunotherapy holds great promise in overcoming the limitations of conventional regimens for cancer therapeutics. There is growing interest among researchers and clinicians to develop novel immune-strategies for cancer diagnosis and treatment with better specificity and lesser adversity. Immunomodulation-based cancer therapies are rapidly emerging as an alternative approach that employs the host’s own defense mechanisms to recognize and selectively eliminate cancerous cells. Recent advances in nanotechnology have pioneered a revolution in the field of cancer therapy. Several nanomaterials (NMs) have been utilized to surmount the challenges of conventional anti-cancer treatments like cytotoxic chemotherapy, radiation, and surgery. NMs offer a plethora of exceptional features such as a large surface area to volume ratio, effective loading, and controlled release of active drugs, tunable dimensions, and high stability. Moreover, they also possess the inherent property of interacting with living cells and altering the immune responses. However, the interaction between NMs and the immune system can give rise to unanticipated adverse reactions such as inflammation, necrosis, and hypersensitivity. Therefore, to ensure a successful and safe clinical application of immunomodulatory nanomaterials, it is imperative to acquire in-depth knowledge and a clear understanding of the complex nature of the interactions between NMs and the immune system. This review is aimed at providing an overview of the recent developments, achievements, and challenges in the application of immunomodulatory nanomaterials (iNMs) for cancer therapeutics with a focus on elucidating the mechanisms involved in the interplay between NMs and the host’s immune system.

show abstract

Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma

Cited by 39 publications

References 69 publications

Immunoengineering in glioblastoma imaging and therapy

Immunoengineering in glioblastoma imaging and therapy

Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics

Contact Info

Product

Resources

About